Research ArticleOriginal Research

Human Papillomavirus (HPV) Vaccination Initiation and Completion Among Adult Males in the United States

Yuqi Guo and Jessamyn Bowling
The Journal of the American Board of Family Medicine July 2020, 33 (4) 592-599; DOI: https://doi.org/10.3122/jabfm.2020.04.190464

References

  1. 1.↵
    Centers for Disease Control and Prevention. Cancers Associated with Human Papillomavirus, United States—2012–2016 | CDC. U.S. Cancer Statistics Data Briefs. https://www.cdc.gov/cancer/uscs/about/data-briefs/no10-hpv-assoc-cancers-UnitedStates-2012-2016.htm. Published 2019. Accessed October 17, 2019.
  2. 2.↵
    1. McLemore MR
    . Gardasil: Introducing the New Human Papillomavirus Vaccine. Clin J Oncol Nurs 2006;10:559–60.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Tumban E,
    2. Peabody J,
    3. Tyler M,
    4. Peabody DS,
    5. Chackerian B
    . VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One 2012;7:e49751.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Zhai L,
    2. Tumban E
    . Gardasil-9: a global survey of projected efficacy. Antiviral Res 2016;130:101–9.
    OpenUrlCrossRef
  5. 5.↵
    1. Walker TY,
    2. Elam-Evans LD,
    3. Yankey D,
    4. et al
    . National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2018. MMWR Morb Mortal Wkly Rep 2019;68:718–23.
    OpenUrlCrossRef
  6. 6.↵
    1. Han JJ,
    2. Beltran TH,
    3. Song JW,
    4. Klaric J,
    5. Choi YS
    . Prevalence of genital human papillomavirus infection and human papillomavirus vaccination rates among US adult men. JAMA Oncol 2017;3:810.
    OpenUrl
  7. 7.↵
    Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. Morbid Mortal Week Rep 2011;60:1705.
    OpenUrl
  8. 8.↵
    US Food and Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. 2018. https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old. Accessed October 17, 2019.
  9. 9.↵
    1. Walsh JM,
    2. McPhee SJ
    . A systems model of clinical preventive care: an analysis of factors influencing patient and physician. Health Educ Q 1992;19:157–75.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Guo Y,
    2. Sims OT
    . HCV health policy developments in response to the national viral hepatitis action plan: a brief update. Soc Work Public Health 2017;32:77–81.
    OpenUrl
  11. 11.↵
    1. Guo Y,
    2. Cheng TC,
    3. Yun Lee H
    . Factors associated with adherence to preventive breast cancer screenings among middle-aged African American women. Soc Work Public Health 2019;34:646–56.
    OpenUrl
  12. 12.↵
    1. Thomas R,
    2. Higgins L,
    3. Widdice L,
    4. Chandler E,
    5. Ding L,
    6. Kahn J
    . Factors associated with HPV vaccination and accuracy of HPV vaccination self-report among 13 to 26 year-old men. J Adolesc Health 2016;12:819–27.
    OpenUrl
  13. 13.↵
    1. Liddon N,
    2. Hood J,
    3. Wynn BA,
    4. Markowitz LE
    . Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 2010;46:113–23.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Spencer JC,
    2. Calo WA,
    3. Brewer NT
    . Disparities and reverse disparities in HPV vaccination: a systematic review and meta-analysis. Prev Med (Baltim) 2019;123:197–203.
    OpenUrl
  15. 15.↵
    1. Ferris DG,
    2. Waller JL,
    3. Miller J,
    4. et al
    . Variables associated with human papillomavirus (HPV) vaccine acceptance by men. J Am Board Fam Med 2009;22:34–42.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Gilbert P,
    2. Brewer NT,
    3. Reiter PL,
    4. Ng TW,
    5. Smith JS
    . HPV vaccine acceptability in heterosexual, gay, and bisexual men. Am J Mens Health 2011;5:297–305.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Dibble KE,
    2. Maksut JL,
    3. Siembida EJ,
    4. Hutchison M,
    5. Bellizzi KM
    . A systematic literature review of HPV vaccination barriers among adolescent and young adult males. J Adolesc Young Adult Oncol 2019;8:495–511.
    OpenUrl
  18. 18.↵
    1. Newman PA,
    2. Logie CH,
    3. Doukas N,
    4. Asakura K
    . HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect 2013;89:568–74.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Gilkey MB,
    2. Moss JL,
    3. McRee AL,
    4. Brewer NT
    . Do correlates of HPV vaccine initiation differ between adolescent boys and girls? Vaccine 2012;30:5928–34.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Franco M,
    2. Mazzucca S,
    3. Padek M,
    4. Brownson RC
    . Going beyond the individual: how state-level characteristics relate to HPV vaccine rates in the United States. BMC Public Health 2019;19:246.
  21. 21.↵
    1. Lu PJ,
    2. Yankey D,
    3. Jeyarajah J,
    4. et al
    . HPV vaccination coverage of male adolescents in the United States. Pediatrics 2015;136:839–49.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Jones M,
    2. Cook R
    . Intent to receive an HPV vaccine among university men and women and implications for vaccine administration. J Am Coll Health 2008;57:23–31. doi:10.3200/JACH.57.1.23-32
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    US Centers for Disease Control and Prevention. The Behavioral Risk Factor Surveillance System (BRFSS) OVERVIEW: BRFSS 2018.; 2019. https://www.cdc.gov/brfss/annual_data/2018/pdf/overview-2018-508.pdf.
  24. 24.↵
    1. Petrosky E,
    2. Bocchini JA,
    3. Hariri S,
    4. et al
    . Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Morb Mortal Wkly Rep 2015;64:300–4.
    OpenUrlPubMed
  25. 25.↵
    1. Bosch FX,
    2. Lorincz A,
    3. Muñoz N,
    4. Meijer C,
    5. Shah KV
    . The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–65.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Brewer NT,
    2. Fazekas KI
    . Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007;45:107–14.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Kessels SJM,
    2. Marshall HS,
    3. Watson M,
    4. Braunack-Mayer AJ,
    5. Reuzel R,
    6. Tooher RL
    . Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 2012;30:3546–56.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Ylitalo KR,
    2. Lee H,
    3. Mehta NK
    . Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US national immunization survey. Am J Public Health 2013;103:164–9.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Smith-McCune KK,
    2. Shiboski S,
    3. Chirenje MZ,
    4. et al
    . Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One 2010;5:e10094.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Meites E,
    2. Szilagyi PG,
    3. Chesson HW,
    4. Unger ER,
    5. Romero JR,
    6. Markowitz LE
    . Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. Am J Transplant 2019;68:698–702.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords